Recurrent Uterine Corpus Sarcoma Clinical Trial
Official title:
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
This phase II trial is studying the side effects and how well ixabepilone works in treating patients with recurrent or persistent leiomyosarcoma of the uterus previously treated with chemotherapy. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PRIMARY OBJECTIVES:
I. To determine the response rate (complete and partial responses by RECIST 1.1) of
ixabepilone in patients with recurrent or persistent leiomyosarcoma of the uterus who have
failed one previous chemotherapy regimen.
II. To determine the nature and degree of toxicity of ixabepilone as assessed by NCI Common
Terminology Criteria for Adverse Events (CTCAE) version 4 in this cohort of patients.
SECONDARY OBJECTIVES:
I. To determine the duration of progression-free survival (PFS) and overall survival (OS).
II. To determine the level of beta-III tubulin expression measured by IHC in women with
leiomyosarcoma.
III. To determine if beta-III tubulin expression as measured by IHC predicts response to
ixabepilone in women with leiomyosarcoma.
OUTLINE:
Patients receive ixabepilone intravenously (IV) over 3 hours on day 1. Courses repeat every
21 days in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up every 3 months for 2 years and
then every 6 months for 3 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01168232 -
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
Completed |
NCT00025220 -
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
|
Phase 2 | |
Completed |
NCT00025506 -
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
|
Phase 2 | |
Terminated |
NCT01012297 -
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
|
Phase 3 | |
Completed |
NCT01548482 -
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Completed |
NCT00114218 -
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
Completed |
NCT01154452 -
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT01098630 -
Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer
|
||
Completed |
NCT01247571 -
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
Completed |
NCT00031629 -
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
|
Phase 2 | |
Completed |
NCT01637961 -
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
|
Phase 2 |